Benicar Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Tabs 5mg—30; 20mg, 40mg—30, 90, 1×30, 10×10, 6×30
Manufacturer
Generic Availability
Mechanism of Action
Benicar Indications
Indications
Benicar Dosage and Administration
Adult
Children
Renal Impairment
No initial dosage adjustment is recommended for patients with moderate to marked renal impairment (CrCl <40mL/min).
Hepatic Impairment
No initial dosage adjustment is recommended for patients with moderate to marked hepatic dysfunction.
Other Modifications
The antihypertensive effect of Benicar was smaller in black patients (usually a low-renin population), as has been seen with ACE inhibitors, beta-blockers and other angiotensin receptor blockers.
Administration
Preparation of Suspension (for 200mL of a 2mg/mL suspension)
- Add 50mL of Purified Water to an amber polyethylene terephthalate (PET) bottle containing twenty Benicar 20mg tablets and allow to stand for a minimum of 5mins.
- Shake the container for at least 1min and allow the suspension to stand for at least 1min.
- Repeat 1-min shaking and 1-min standing for 4 additional times.
- Add 100mL of ORA-Sweet® and 50mL of ORA-Plus®1 to the suspension and shake well for at least 1min.
- The suspension should be refrigerated at 2–8° C (36–46° F) and can be stored for up to 4 weeks.
- Shake the suspension well before each use and return promptly to the refrigerator.
Benicar Contraindications
Contraindications
Benicar Boxed Warnings
Boxed Warning
Benicar Warnings/Precautions
Warnings/Precautions
Benicar Pharmacokinetics
Absorption
Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the GI tract.
The absolute bioavailability of olmesartan is ~26%.
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1–2 hours. Food does not affect the bioavailability of olmesartan.
Distribution
Volume of distribution: ~17 L. Plasma protein bound: 99%; does not penetrate red blood cells.
Elimination
Total plasma clearance of olmesartan is 1.3 L/h, with a renal clearance of 0.6 L/h.
Renal (~35–50%), fecal via the bile (remainder). Half-life: ~13 hours.
Benicar Interactions
Interactions
See Contraindications. Concomitant K+-sparing diuretics, K+ supplements, K+-containing salt substitutes may cause hyperkalemia. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors; monitor renal function periodically in elderly and/or volume-depleted. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Take at least 4hrs before colesevelam HCl dose. May increase lithium levels; monitor.
Benicar Adverse Reactions
Adverse Reactions
Benicar Clinical Trials
Benicar Note
Not Applicable
Benicar Patient Counseling
Images
